Friday 6 November 2026
Export WST’s income statement to Excel — free account
West Pharmaceutical Services, Inc.
WST Healthcare Medical Instruments & Supplies
West Pharmaceutical Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 billion, up 6.25% from fiscal 2024.
- Revenue
- +8.69%
- EPS
- +56.7%
- Free cash flow
- +12.3%
- Total debt
- +0.10%
Quarter to September 2026, against a year earlier
392.97
15.81
−3.87%
Follow WST
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
41.33 | 45.62 | 33.33 | 40.28 |
+8 more quarters Free account |
P/S ratio |
7.68 | 7.64 | 5.60 | 6.47 | |
P/FCF ratio |
58.05 | 58.69 | 39.73 | 42.77 | |
P/Operating CF |
137.74 | 204.98 | 200.74 | 79.22 | |
P/B ratio |
8.79 | 8.50 | 6.03 | 6.26 | |
Price to Tangible BV |
9.15 | 8.84 | 6.28 | 6.50 | |
EV/Sales |
7.61 | 7.57 | 5.50 | 6.28 | |
EV/EBITDA |
26.79 | 29.22 | 21.32 | 25.52 | |
EV/Operating CF |
39.48 | 38.03 | 24.78 | 25.58 | |
EV/FCF |
57.47 | 58.15 | 39.03 | 41.51 | |
Quick Ratio |
1.88 | 1.79 | 1.79 | 2.09 | |
Current Ratio |
2.82 | 2.82 | 2.71 | 3.02 | |
Net Debt/EBITDA |
(0.83) | (1.03) | (1.43) | (2.89) | |
Debt/Assets |
5.00% | 4.98% | 4.93% | 4.75% | |
Debt/Equity |
0.07 | 0.07 | 0.07 | 0.06 | |
Asset Turnover |
0.83 | 0.83 | 0.83 | 0.78 | |
Operating CF/Net income |
0.89 | 0.81 | 0.65 | 1.90 | |
Capex/Depreciation |
(0.85) | (0.94) | (0.94) | (1.62) | |
Interest Coverage |
70.37 | 68.88 | 93.21 | (783.00) | |
Research and Development Expense of Revenue |
2.09% | 2.26% | 1.87% | 2.71% | |
Selling, General and Administrative Expense of Revenue |
12.91% | 13.48% | 11.78% | 13.29% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
0.49% | 1.25% | 0.78% | 0.83% | |
Graham Net Nets |
0.03 | 0.03 | 0.04 | 0.04 | |
Graham Number |
92.25 | 86.48 | 83.83 | 82.16 | |
Earnings Yield |
2.42% | 2.19% | 3.00% | 2.48% | |
Free Cash Flow Yield |
1.72% | 1.70% | 2.52% | 2.34% | |
Revenue per Share |
12.42 | 12.32 | 11.73 | 11.13 | |
Operating CF per Share |
2.69 | 1.75 | 1.25 | 3.47 | |
Capex per Share |
(0.56) | (0.61) | (0.59) | (1.05) | |
Free Cash Flow per Share |
2.14 | 1.14 | 0.66 | 2.42 | |
Cash per Share |
6.59 | 6.16 | 7.24 | 10.94 | |
Shareholders Equity per Share |
42.16 | 42.23 | 41.53 | 43.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
42.16 | 42.23 | 41.53 | 43.93 | |
Free Cash Flow |
150.40 | 80.80 | 47.20 | 175.00 | |
Working Capital |
1,172.20 | 1,167.00 | 1,152.80 | 1,323.30 | |
Capital Expenditures |
(39.10) | (43.20) | (42.70) | (76.10) | |
Net Current Asset Value |
724.00 | 721.30 | 707.40 | 884.20 | |
EV/EBIT |
33.12 | 37.01 | 27.06 | 33.00 | |
Capex to Sales |
0.04 | 0.05 | 0.05 | 0.09 | |
Price to Operating Income |
33.45 | 37.36 | 27.55 | 34.01 | |
| Other line items | |||||
Average Receivables |
686.60 | 647.20 | 614.60 | 563.45 | |
Average Payables |
252.60 | 245.85 | 240.35 | 246.50 | |
Average Inventory |
451.35 | 434.25 | 420.65 | 410.45 | |
Average Assets |
4,083.25 | 4,014.60 | 3,864.00 | 3,956.70 | |
Average Common Equity |
3,009.85 | 2,959.65 | 2,836.75 | 2,929.15 |
Columns are period end dates · fundamentals updated 2 Nov 2026